Bilaal.Raja
Company record

UPB  Upstream Bio, Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-11 and not restated since.
Healthcare

Scale

Market cap
$276m
Revenue TTM
$3m
Net income TTM
$-156m
Free cash flow
—
Composite score
—
Sector rank
#2660

Valuation

P / E
—
EV / EBITDA
—
EV / sales
4.7
FCF yield
—
Yield vs 10-yr
-61.97pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4,955.7%
EBITDA margin
-5,376.2%
ROE
-57.8%
ROIC
-1,761.5%
Revenue growth
—

Insider activity, last 90 days

Net open-market
$-0.03m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In connection with the ATM Program, we filed the ATM Prospectus on March 26, 2026 for the offer and sale of up to $150.0 million of shares of common stock from time to time through the sales agent.Upstream Bio, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-11

Read the full passage →